EcoDrugPlus

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSLCAG00010021897
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSLCAG00010019454
Gene Symbol: CACNA1DA
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSLCAG00010017615
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, A

Ensembl ID : ENSLCAG00010016257
Gene Symbol: CACNA1SA
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSLCAG00010021549
Gene Symbol: CACNA1SB
1 Cross references
199 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSLCAG00010025823
Gene Symbol: CACNA1BA
1 Cross references
219 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSLCAG00010016281
Gene Symbol: CACNA1AB
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSLCAG00010004537
Gene Symbol: CACNA2D1A
1 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSLCAG00010005421
Gene Symbol: CACNA2D2A
1 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSLCAG00010023698
Gene Symbol: LOC108872768
4 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSLCAG00010023714
Gene Symbol: CACNB2A
4 Cross references
201 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSLCAG00010019670
Gene Symbol: CACNB3A
4 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).